arrow
H

Helmut R. Salih

University of Hamburg
H指数:66
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
2024-12-030
OAAI
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients
2024-11-260
OAAI
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients
2024-10-140
OAAI
Phase I trial of a personalized multi-peptide vaccine combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in chronic lymphocytic leukemia (CLL) patients

一期临床试验:在慢性淋巴细胞白血病(CLL)患者中,接受Bruton-Tyrosine-Kinase抑制剂(BTKi)治疗期间,个性化多肽疫苗与TLR1/2配体XS15联合应用。

2024-09-010
PRE
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
2024-03-283
OAAI
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

首次人体临床试验的方案,以评估双特异性CD276xCD3抗体CC-3在结直肠癌患者中的安全性,耐受性和初步疗效 (CoRe_CC-3)

2024-02-120
OAAI
TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

基于TOFIMS质谱的免疫抗体优化肿瘤抗原鉴定

2023-11-177
OAAI
Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells

急性髓系白血病的免疫监视是由白血病祖细胞上的HLA呈递抗原介导的

2023-10-179
OAAI
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
2023-08-1812
OAAI
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

评估具有可测量残留疾病的AML患者中Fc优化的FLT3抗体FLYSYN的I期研究

2023-08-176
OAAI